Vaccines: the road ahead

The UK approved the first COVID-19 vaccine in early December, and the pandemic entered a new phase. While this is certainly a moment for optimism, vaccines bring new challenges around efficacy, distribution and public resistance. This week’s panel includes Caroline Naumann, Associate Director for Crisis and Security Consulting and also our COVID-19 Advisory Lead in EMEA,  and Joseph Smith, Senior Analyst responsible for providing analysis on international business issues as well as one of our leaders on analysis of the vaccine rollout.